Poor survival in stage IIB/C (T4N0) compared to stage IIIA (T1-2 N1, T1N2a) colon cancer persists even after adjusting for adequate lymph nodes retrieved and receipt of adjuvant chemotherapy

A survival paradox between Stage IIB/C and Stage IIIA colon cancers exists. It is unclear how adequate lymph nodes dissection (LN) and post-surgery chemotherapy contribute to the survival paradox. We intended to assess the impact of these two factors on the survival paradox. We evaluated 34,999 pati...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMC cancer 2016-07, Vol.16 (1), p.460-460, Article 460
Hauptverfasser:	Chu, Quyen D, Zhou, Meijiao, Medeiros, Kaelen L, Peddi, Prakash, Kavanaugh, Mindie, Wu, Xiao-Cheng
Format:	Artikel
Sprache:	eng
Schlagworte:	Accountability Adjuvant treatment Adolescent Adult Aged Cancer Cancer therapies Care and treatment Chemotherapy Chemotherapy, Adjuvant Cohort Studies Colleges & universities Colon cancer Colonic Neoplasms - drug therapy Colonic Neoplasms - mortality Colonic Neoplasms - pathology Colonic Neoplasms - surgery Colorectal cancer Comorbidity Comparative studies Confidence intervals Development and progression Education Follow-Up Studies Health insurance Health sciences Humans Hypotheses Kaplan-Meier Estimate Lung Neoplasms Lymph Node Excision Lymph Nodes - pathology Lymphatic Metastasis Lymphatic system Medical prognosis Middle Aged Neoplasm Staging Survival analysis Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A survival paradox between Stage IIB/C and Stage IIIA colon cancers exists. It is unclear how adequate lymph nodes dissection (LN) and post-surgery chemotherapy contribute to the survival paradox. We intended to assess the impact of these two factors on the survival paradox. We evaluated 34,999 patients diagnosed with stage IIIA or stage IIB/C colon cancer in 2003-2012 from the National Cancer Data Base. The 5-year overall survival (OS) was 73.5 % for stage IIIA and 51.1 % for stage IIB/C (P
ISSN:	1471-2407 1471-2407
DOI:	10.1186/s12885-016-2446-3